[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"echocardiography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:echocardiography":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,43,66,105,131,155,177,203,225,248,277,302,321,342,370,401,435,460,484],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644168","assessment-of-cardiac-and-carotid-ultrasound-measurements-in-a-cohort-of-healthy-children-in-italy-100644168",false,"NCT07666451","Assessment of Cardiac and Carotid Ultrasound Measurements in a Cohort of Healthy Children in Italy","NORMECO","Inclusion Criteria:\n\nAge between 0 and 18 years (inclusive) Availability of demographic and anthropometric data Negative past and recent medical history for chronic or acute diseases Adequate quality of echocardiographic evaluation Written informed consent obtained from parent\u002Flegal guardian and assent from the minor when applicable\n\nExclusion Criteria:",true,"ALL","0 Years","18 Years",{"count":21,"type":22},1400,"ESTIMATED","OBSERVATIONAL","This observational ambispective cohort study aims to establish reference values for cardiac structure and function, coronary artery dimensions, and carotid intima-media thickness (cIMT) in a healthy pediatric population living in Italy. Healthy children aged 0-18 years undergoing cardiologic evaluation will be enrolled. Echocardiographic and carotid ultrasound parameters will be collected together with anthropometric and demographic data. The study includes both retrospective and prospective cohorts.",[26,27,28],"Cardiovascular Imaging","Echocardiography","Carotid Intima-Media Thickness",[28,27,26],"RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":34},"2026-03-17",{"date":38,"type":22},"2031-12-31",{"name":40,"class":41},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100635855","digitheart-echo-study-100635855","NCT07558109","DigitHeart Echo Study","Cardiac Anatomical and Mechanical Properties Prediction From Electrocardiography (ECG) With Multi-Modal Representation Learning","DigitHeart-SHD","Inclusion Criteria:\n\n* aged ≥ 18 years old\n* planned to have echocardiography performed\n* voluntarily agree to participate in the trial.\n\nExclusion Criteria:\n\n* had echocardiography performed within 1 month\n* pacemaker rhythm on ECG\n* dextrocardia\n* complex adult congenital heart disease\n* ventricular assist device implantation.",{"count":52,"type":22},478,"Eligible patients will be interviewed by research staff to explain the trial design and rationale. Written informed consent will be obtained from patients who voluntarily agree to participate. Demographics and medical history will be obtained. A 12-lead ECG will be performed; it has not been performed within 6 months. A photo of the 12-lead ECG will be taken by research staff using the DigitHeart-2 smartphone application. Predictions from DigitHeart-2\u002FMERL-ECHO and other machine learning models hosted by the investigator team for each of the target anatomical and mechanical properties will be recorded. The cardiologist in charge of the patient, who is blinded to the prediction results from DigitHeart-2\u002FMERL-ECHO, will perform echocardiography according to American Society of Echocardiography guidelines, which will serve as the gold standard for accuracy evaluation.",[55,56,27],"Heart Disease","Electrocardiograph","2026-04-22",{"date":59,"type":34},"2026-04-30",{"date":61,"type":34},"2025-02-14",{"date":63,"type":22},"2027-02-14",{"name":65,"class":41},"The University of Hong Kong",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":42},"100631250","coronoary-microcirculation-analysis-network-100631250","NCT07498231","COronoary Microcirculation Analysis NETwork","Assessment of Risk Factors for Coronary Circulatory and Microcirculatory Disorders, Comparison of Invasive and Non-Invasive Diagnostic Methods, and Evaluation of the Impact of Individualized Pharmacotherapy Optimization on Patients' Quality of Life","COMA-NET","Inclusion Criteria:\n\na. Chronic coronary syndrome c. Anginal symptoms \\> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Angiographically significant coronary artery stenosis or FFR \\\u003C 0.8\n2. Renal insufficiency with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²\n3. Left ventricular ejection fraction \\\u003C 40%\n4. Hypertrophic cardiomyopathy\n5. Acute coronary syndrome within \\\u003C 90 days\n6. Percutaneous coronary intervention (PCI) within \\\u003C 90 days\n7. Previous coronary artery bypass grafting (CABG)\n8. Anemia \\\u003C 10 g\u002FdL or thrombocytopenia \\\u003C 100,000\u002FµL\n9. Intraventricular conduction disturbances preventing ST-T segment assessment\n10. Severe concomitant valvular heart disease\n11. Active malignancy\n12. Type 1 diabetes mellitus\n13. Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing \\> 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly cannulate coronary ostia)\n14. Pregnancy\n15. Heart failure ≥ NYHA class III\n16. Asthma or COPD with severe irreversible airflow obstruction\n17. Atrial fibrillation\n18. Second- or third-degree atrioventricular block without pacemaker implantation (IPG)\n19. Manifest pre-excitation on ECG or history of AVRT episodes without prior ablation of the accessory pathway","75 Years",{"count":76,"type":22},180,"INTERVENTIONAL",[79],"NA","COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.\n\nPharmacotherapy based on the endotype established during intracoronary assessment will be introduced in the intervention arm of the study. The primary endpoint is the change in the Seattle Angina Questionnaire (SAQ) score from baseline to 3 months. Secondary endpoints include the diagnostic accuracy of transthoracic echocardiographic coronary flow velocity reserve (CFVR), the incidence of adverse events, associations between biomarkers and coronary microvascular dysfunction (CMD), and the identification of risk factors for specific CMD endotypes.\n\nParticipants will undergo invasive functional evaluation of the coronary microcirculation, measurement of echocardiographic CFVR, and analysis of selected circulating biomarkers. The study cohort will be followed up at three and six months and will include reassessment of quality of life (Seattle Angina Questionnaire, EuroQol 5-Dimensions 5-Level questionnaire, 12-item Short Form Health Survey), anxiety (Generalized Anxiety Disorder-7 score), and functional status (6-minute walk test).\n\nThe study began in October 2025. Primary completion is anticipated in October 2027, and the overall study completion date is expected in March 2028.",[82,83,84,85,86,27,87],"Coronary Artery Disease","Microcirculation Resistance","Microcirculation; Biomarkers; Myocardial Ischemia","Microcirculatory Dysfunction","Microcirculatory Status","Doppler Echocardiography",[89,90,91,92,93,94,95],"coma.net","coma-net","coronary microcirculation","ANOCA","INOCA","angina with non-obstructive coronary arteries","ischemia with non-obstructive coronary arteries","2026-04-02",{"date":98,"type":34},"2026-04-08",{"date":100,"type":34},"2025-10-10",{"date":102,"type":22},"2028-03",{"name":104,"class":41},"Medical University of Bialystok",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":130},"100622998","gls-in-difficult-cpb-weaning-100622998","NCT07390903","GLS in Difficult CPB Weaning","Global Longitudinal Strain as a Predictor of Difficult Separating From Cardiopulmonary Bypass","Inclusion Criteria\n\n* Age \\> 18 years.\n* Scheduled for elective cardiac surgery requiring cardiopulmonary bypass (CPB).\n* Provided written informed consent to participate.\n* Eligible surgical procedures include:\n\n  * Isolated mitral valve replacement or repair.\n  * Isolated aortic valve replacement or repair.\n  * Isolated coronary artery bypass grafting (CABG).\n  * Combined valve and CABG surgery.\n  * Multiple valve replacement or repair.\n  * Surgery involving the ascending aorta or aortic arch.\n\nExclusion Criteria\n\n* Emergency cardiac surgery.\n* Redo cardiac surgery.\n* Contraindications to transesophageal echocardiography (TEE).\n* Critical preoperative conditions, including:\n\n  * Ongoing inotropic drug therapy.\n  * Preoperative mechanical circulatory support (e.g., IABP, ECMO, VAD).\n  * Requirement for mechanical ventilation.\n  * Preoperative atrial fibrillation.",{"count":113,"type":22},213,"The goal of this observational study is to learn whether global longitudinal strain (GLS), measured by echocardiography, can predict difficulty separating from cardiopulmonary bypass (CPB) in adults undergoing elective cardiac surgery.\n\nThe main questions it aims to answer are:\n\n* Can preoperative GLS measurement predict difficult separation from CPB?\n* Are GLS values associated with outcomes such as intensive care unit (ICU) stay, hospital stay, cardiac biomarkers, or 30-day mortality?\n\nParticipants will:\n\n* Undergo standard cardiac surgery requiring CPB\n* Have echocardiographic assessments (TTE before and after surgery)\n* Have their recovery and outcomes monitored, including ICU and hospital stay, postoperative labs, and survival within 30 days",[116,117,118,27,119,120],"Cardiopulmonary Bypass","Coronary Artery Bypass","Heart Valve Diseases","Intraoperative Complications","Postoperative Complications (Cardiopulmonary)","2026-02-01",{"date":123,"type":34},"2026-02-05",{"date":123,"type":22},{"date":126,"type":22},"2026-08-30",{"name":128,"class":129},"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","OTHER_GOV",2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100569501","value-of-speckle-tracking-echocardiography-inflammatory-bowel-disease-patients-100569501","NCT06695065","Value of Speckle Tracking Echocardiography Inflammatory Bowel Disease Patients","Value of Speckle Tracking Echocardiography in Early Assessment of Cardiac Function in Inflammatory Bowel Disease Patients","Inclusion Criteria:\n\n* Age (18-60) yrs.\n* Both sexes.\n* Patients with IBD either in active form or in remission.\n\nExclusion Criteria:\n\n* Patients with ischemic heart disease. -Patients with other comorbidities affecting heart as uncontrolled hypertension or diabetes. -\n* Pregnant females.\n* Malignancy","60 Years",{"count":140,"type":22},100,"Value of speckle tracking echocardiography in early assessment of cardiac function in inflammatory bowel disease .",[27,143,144],"Inflammatory Bowel Diseases","Cardiac Function","NOT_YET_RECRUITING","2025-09-29",{"date":148,"type":34},"2025-10-02",{"date":150,"type":22},"2025-10-01",{"date":152,"type":22},"2027-12-01",{"name":154,"class":41},"Assiut University",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":162,"targetDuration":164,"studyType":23,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100598050","clinical-performance-evaluation-of-a-diagnostic-ultrasound-system-100598050","NCT07066449","Clinical Performance Evaluation of a Diagnostic Ultrasound System","Clinical Performance Evaluation of the Vivid Pioneer Diagnostic Ultrasound System","Inclusion Criteria:\n\n1. Adults ≥ 18 years old, have autonomous capacity;\n2. Subjects who are required to undergo intraoperative transesophageal echocardiography according to the current clinical practice standards;\n3. Agree to participate in this study and have signed the subject Informed Consent Form.\n\nExclusion Criteria:\n\n1. Subjects who have been previously enrolled in this study or are participating in other clinical trials;\n2. Subjects with any medical emergency condition requiring urgent treatment;\n3. Pregnant females;\n4. Subjects with absolute contraindications of TEE (congenital or acquired upper digestive tract diseases, such as active upper gastrointestinal hemorrhage, esophageal obstruction or stenosis, esophageal tumor, esophageal lacerations and perforations, esophageal diverticula) or relative contraindications (changes in consciousness or lack of cooperation, history of cervical and mediastinal radiotherapy, history of recent esophageal surgery, esophageal varicosity, clotting disorders, cervical disease and injury, active esophagitis, active gastrointestinal ulcers, hiatal hernia, poor cardiopulmonary function, airway damage, pharyngeal space-occupying lesions, etc.), who are expected to be at high risks;\n5. Any other subjects who should not participate in this study in the investigator's opinion.",{"count":163,"type":22},60,"1 Day","Subjects who are required to undergo transesophageal echocardiography according to the current clinical practice standards will be eligible for enrollment. Subjects will be screened for enrollment in this study against the inclusion and exclusion criteria. After successful screening and enrollment of subjects, the investigators will first use the investigational device to conduct transthoracic echocardiography (TTE), followed by transesophageal echocardiography (TEE). TEE will be conducted after the subject has been anesthetized. To avoid any delay in diagnosis and treatment, after the scan with the investigational device is completed, the probe will be reserved and the console will be switched to the existing commercial cardiac diagnostic ultrasound device in the study site for intraoperative guidance. In the study, each investigator will evaluate the overall image quality, user interface, workflow, user preferences, product preset, and functions of the system, as well as the device's safety and stability and fill out a user feedback questionnaire provided by the Sponsor.",[27],"2025-09-15",{"date":169,"type":34},"2025-09-19",{"date":171,"type":34},"2025-08-12",{"date":173,"type":22},"2026-04",{"name":175,"class":176},"GE Healthcare","INDUSTRY",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100603207","a-multi-center-study-on-artificial-intelligence-based-quantitative-evaluation-of-echocardiography-100603207","NCT07133516","A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography","MAIQUEE","Inclusion Criteria:\n\n1. Age ≥18 - 80 years;\n2. Types of diseases (8 in total, 200 cases each):\n\n   1. Normal heart\n   2. Coronary heart disease (with segmental thinning and abnormal movement)\n   3. Valve disease (valve stenosis or reflux)\n   4. Hypertensive heart disease\n   5. Atrial fibrillation\n   6. Heart failure\n   7. Dilated cardiomyopathy\n   8. Hypertrophic cardiomyopathy\n\nExclusion Criteria:\n\n1. Patients with congenital heart disease\n2. Patients with poor image quality","80 Years",{"count":186,"type":22},1600,"This project aims to collaborate with multiple medical institutions to verify the accuracy, stability, and clinical application value of AI algorithms in echocardiographic quantitative measurement through multi-center clinical research. Specific objectives include:\n\n1. Compare the automatic measurement results of AI with the manual measurement data from physicians of different levels, and analyze the measurement deviation and consistency of AI in key parameters such as intracardiac diameter, volume, and function.\n2. Investigate whether AI-assisted measurement can significantly reduce echocardiogram analysis time and optimize clinical workflows. Through multi-center data validation, establish a standardized reference system for AI ultrasound measurement, promote the promotion and application of AI technology in medical institutions at all levels, and reduce diagnostic differences between different hospitals and physicians.\n3. Exploring the application of AI in special cases: Assessing the measurement stability of AI algorithms in complex cases (such as cardiomyopathy, valvular disease, coronary heart disease, etc.), and optimizing AI models to meet broader clinical needs.",[189,190,191,27],"Artificial Intelligence (AI)","Artificial Intelligence (AI) in Diagnosis","Cardiovascular Diseases (CVD)",[189,190,191,27],"2025-08-18",{"date":195,"type":34},"2025-08-21",{"date":197,"type":34},"2025-07-22",{"date":199,"type":22},"2026-07-31",{"name":201,"class":41},"First Hospital of China Medical University",37,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":212,"studyType":23,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":42},"100595254","echocardiography-guided-tavr-echo-tavr-100595254","NCT07030062","Echocardiography Guided TAVR (Echo TAVR)","Transcatheter Aortic Valve Replacement With Echocardiography Guidance","Inclusion Criteria:\n\n1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m\u002Fs, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2\u002Fm2);\n2. a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;\n3. chronic kidney disease and refuse to receive contrast agents or radiation exposure.\n\nExclusion Criteria:\n\nRequired hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.",{"count":211,"type":22},20,"1 Month","Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.",[215,27],"Transcatheter Aortic Valve Replacemen","2025-06-12",{"date":218,"type":34},"2025-06-19",{"date":220,"type":34},"2025-02-18",{"date":222,"type":22},"2025-12-31",{"name":224,"class":41},"Pan Xiangbin",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":16,"sex":17,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":42},"100557105","impact-of-echocardiography-on-management-of-critically-ill-neonates-100557105","NCT06533787","Impact of Echocardiography on Management of Critically Ill Neonates","Inclusion Criteria:\n\n* All neonates ( age 0 to 28 days) admitted to the NICU of Sohag University Hospital during the period of the study in whom manifestations of hemodynamic instability or critical illness were elected regardless of gestational age, weight, gender, or type of disease.\n\nExclusion Criteria:\n\n* Failure to obtain informed consent .\n* Presence of congenital heart disease apart from PDA , PFO \\& small ASD .","2 Hours","28 Days",{"count":234,"type":22},50,"The goal of the study was to estimate the outcome (mortality and morbidity) among hemodynamically unstable neonates, as well as the time to return to hemodynamic stability following the use of ECHO in the management of hemodynamically unstable neonates.",[237,27,238],"Critical Illness","Neonatology","2025-05-31",{"date":241,"type":34},"2025-06-03",{"date":243,"type":34},"2024-08-01",{"date":245,"type":22},"2025-08",{"name":247,"class":41},"Sahar Abozkaly Mahmoud",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":77,"phases":259,"briefSummary":260,"conditions":261,"keywords":266,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":130},"100495084","integrated-echocardiography-and-chest-ultrasound-assessment-of-lung-recruitment-in-preterm-infants-100495084","NCT05726578","Integrated Echocardiography and Chest Ultrasound Assessment of Lung Recruitment in Preterm Infants","Integrated Echocardiography and Chest Ultrasound Assessment of Lung Recruitment in Preterm Infants Using High Frequency Ventilation","Inclusion Criteria:\n\n* Infants will be enrolled if they are 32 to 37 weeks of gestational age, have respiratory distress (RD) in the first 24 h of life, intubated and have invasive respiratory support using HFOV. Signs of RD are tachypnea (respiratory rate \\> 60\u002Fmin), grunting, nasal flaring, chest retraction, and need of oxygen supplementation or other respiratory support.\n\nExclusion Criteria:\n\n1. Known major congenital anomalies including congenital heart diseases.\n2. Fetal hydrops.\n3. Babies with congenital heart diseases","1 Hour","3 Days",{"count":258,"type":22},72,[79],"The primary aim of this work is to evaluate the role of high frequency oscillatory ventilation (HFOV) in recruitment of lung in preterm newborns 32 to 37 weeks gestational age with moderate to severe respiratory distress. The secondary aim is to evaluate the role of chest ultrasound in monitoring of lung recruitment in comparison to routine chest x ray in those babies. Also cardiac hemodynamics will be assesed using functional echocardiography.",[262,27,263,264,265],"Ventilator Lung","Chest Ultrasound","High Frequency Ventilation","Lung Recruitment",[267],"Premature infants","2025-05-24",{"date":270,"type":34},"2025-05-28",{"date":272,"type":34},"2024-07-01",{"date":274,"type":22},"2025-07-01",{"name":276,"class":41},"Alexandria University",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":74,"enrollmentInfo":284,"targetDuration":164,"studyType":23,"phases":4,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":4},"100575323","effect-of-thoracic-epidural-anesthesia-on-left-ventricular-functions-a-strain-echocardiography-study-100575323","NCT06770790","Effect of Thoracic Epidural Anesthesia on Left Ventricular Functions: A Strain Echocardiography Study","TEA-strain","Inclusion Criteria:\n\nElective payment options ASA I-III Ages 18-75\n\nExclusion Criteria:\n\n1. Refusal at enrollment\n2. Request for withdrawal from the study\n3. Inability to give informed consent\n4. Emergency surgery\n5. Bleeding diathesis\n6. Presence of contraindications to the LA agents used in this study\n7. Use of chronic opioids\n8. Psychiatric disorders\n9. Presence of infection at the injection site",{"count":285,"type":22},23,"Post-thoracic surgery pain management thoracic epidural catheter is the most commonly used method.\n\nThoracic epidural anesthesia, in which cardiac sympathetic nerves (T1-T5) are involved in neural blockade, is the focus of our research. Many studies have shown a decrease in inotropic status (intrinsic function) after blockade of cardiac sympathetic innervation with thoracic epidural anesthesia (TEA).We want to examine the cardiac effects of TEA with strain echocardiography, which is an advanced echocardiography method. Therefore, we aimed to investigate the effect of TEA on left ventricular functions with strain echocardiography.",[288,27],"Thoracal Epidural Block",[290,291,292,293],"thoracic epidural anesthesia","left ventricle","strain echocardiography","cardiac function","2025-01-07",{"date":296,"type":34},"2025-01-13",{"date":298,"type":22},"2025-01-10",{"date":123,"type":22},{"name":301,"class":41},"Aydin Adnan Menderes University",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":74,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100575325","effect-of-left-erector-spinae-plane-block-on-left-ventricular-functions-100575325","NCT06770816","Effect of Left Erector Spinae Plane Block on Left Ventricular Functions","ESP-LV ECHO","Inclusion Criteria:\n\nPatients undergoing elective left-sided thoracic surgery ASA I-III 18-75 years of age\n\nExclusion Criteria:\n\n1. Refusal at enrollment\n2. Request for withdrawal from the study\n3. Inability to give informed consent\n4. Emergency surgery\n5. Bleeding diathesis\n6. Presence of contraindications to the LA agents used in this study\n7. Use of chronic opioids\n8. Psychiatric disorders\n9. Presence of infection at the injection site",{"count":285,"type":22},"Many studies have shown a decrease in inotropic status (intrinsic function) after blockade of cardiac sympathetic innervation with thoracic epidural anesthesia (TEA) (4,5). There is no study in the literature investigating the cardiac effects of left thoracic ESP block. We think that left thoracic ESP block, like TEA, may also have cardiac effects. Therefore, we aimed to investigate the effect of left thoracic ESP block on left ventricular functions with transthoracic echocardiography (TTE).",[312,27],"Erector Spina Plan Block",[314,291,315],"erector spina plan block","echocardiography",{"date":296,"type":34},{"date":298,"type":22},{"date":319,"type":22},"2026-02-02",{"name":301,"class":41},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":77,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":340,"locationsCount":42},"100573178","echo-acquisition-despite-geographic-separation-by-replication-of-human-movements-eager-100573178","NCT06742905","Echo Acquisition Despite Geographic Separation by Replication of Human Movements (EAGER)","Echocardiographic Acquisition With Geographic Separation of Patients and Sonographers With Roboot Assistance (EAGER)","EAGER","Inclusion Criteria:\n\n* Having a conventional echocardiogram\n\nExclusion Criteria:\n\n* Declined consent to undergo both examinations",{"count":234,"type":22},[79],"Echocardiography is a cornerstone of modern cardiology management, but access in rural and remote areas is limited. We have developed a robot (\"Edler\" named after the originator of echocardiography) which enables a sonographer to complete an examination at a distance. This study seeks to compare the images obtained by both methods, the completeness of the exam over a feasible time, and to identify particular components of the exam that are difficult to obtain using the robot.",[27],[27],"2024-12-16",{"date":336,"type":34},"2024-12-19",{"date":338,"type":22},"2025-01-15",{"date":222,"type":22},{"name":341,"class":41},"Baker Heart and Diabetes Institute",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":74,"enrollmentInfo":349,"targetDuration":4,"studyType":77,"phases":351,"briefSummary":353,"conditions":354,"keywords":357,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":4},"100561171","phase-4-effect-of-small-interfering-rna-inclisiran-on-carotid-plaques-as-assessed-by-carotid-ultrasound-100561171","NCT06586684","Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound","The Effect of Small Interfering RNA Inclisiran on Carotid Plaques in Patients with Atherosclerosis: a Real-world Study Using Carotid Ultrasound.","Inclusion Criteria:\n\n* Patients with carotid plaques as indicated by ultrasound\n* Men and women aged 18-75 years;\n* LDL-C \\>3.4 mmol\u002FL without regular statin therapy or LDL-C \\>1.8 mmol\u002FL after 4 weeks of statin lipid-lowering therapy.\n\nExclusion Criteria:\n\n* \\- Known allergies or contraindications to PCSK9 inhibitors and\u002For statin therapy;\n* Prior use of PCSK9 inhibitors;\n* Prior history of hemorrhagic stroke;\n* Prior coronary artery bypass grafting or coronary intervention;\n* Inability to perform OCT imaging or unclear imaging;\n* Severe renal insufficiency (creatinine clearance \\< 30 mL\u002Fmin);\n* Severe hepatic dysfunction;\n* Baseline triglycerides \\> 5.6 mmol\u002FL;\n* Pregnant or lactating women;\n* Life expectancy not exceeding 1 year;\n* In the judgment of the investigator, unsuitable for this study for any reason.",{"count":350,"type":22},40,[352],"PHASE4","Current understanding suggests that the majority of cardiovascular events are driven by vulnerable plaques. Nonetheless, the impact of PCSK9 inhibitors on the stability of carotid plaques remains insufficiently elucidated, with a notable scarcity of relevant clinical studies. This investigation seeks to address this gap through a real-world study conducted among patients with arterial sclerosis in Asia. The primary aim is to evaluate the effects of small interfering RNA (inclisiran) on carotid plaque characteristics as assessed by ultrasound, thereby contributing valuable data to inform clinical practice.",[355,356,27],"Carotid Plaque","Hyperlipidemia",[358,359,27,360],"inclisiran","carotid plaque","hyperlipidmia","2024-09-04",{"date":363,"type":34},"2024-09-19",{"date":365,"type":22},"2024-09-20",{"date":367,"type":22},"2026-09-30",{"name":369,"class":41},"First Affiliated Hospital of Xinjiang Medical University",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":378,"targetDuration":380,"studyType":23,"phases":4,"briefSummary":381,"conditions":382,"keywords":385,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":400},"100560985","multimodal-cardiac-imaging-registry-in-patients-with-atrial-fibrillation-100560985","NCT06584266","Multimodal Cardiac Imaging Registry in Patients with Atrial Fibrillation","Multimodal, Multicentre Registry of Clinical and Imaging Data to Develop Predictive Models Based on Artificial Intelligence to Support the Diagnostic and Therapeutic Process for Patients with Atrial Fibrillation Undergoing Catheter Ablation and Cardioversion.","IMAGE-AF","Inclusion Criteria:\n\n\\- All patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period (all consecutive patients).\n\nExclusion Criteria:\n\nAge\\<18, lack of informed, written consent to the TEE",{"count":379,"type":22},3000,"12 Months","The goal of this observational registry is to collect a curated dataset of multimodal imaging data that will serve for development of artificial-intelligence based solutions for prediction of risk and outcomes in patients with atrial fribrillation.\n\nType of study: observational study\n\nStudy Participants: Patients with atrial fibrillation or atrial flutter who undergo clinically indicated transesophageal echocardiography before catheter ablation or cardioversion.\n\nWe hypothesize, that automatic analysis of video images of transthoracic echocardiography with deep learning combined with clinical data can predict the presence of left atrial appendage thrombus (LAT). Therefore, our main aim is to create and validate an artificial intelligence model to predict the presence of LAT based on automatic analysis of transthoracic echocardiography with artificial intelligence.",[383,384,189,27],"Atrial Fibrillation and Flutter","Heart Failure",[386,387,388,389,390,391],"artificial intelligence","left atrial thrombus","transesophageal echocardiography","left atrial appendage thrombus","ablation","left atrial function","2024-08-31",{"date":361,"type":34},{"date":395,"type":34},"2024-01-01",{"date":397,"type":22},"2027-09",{"name":399,"class":41},"University in Zielona Góra",7,{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":77,"phases":411,"briefSummary":412,"conditions":413,"keywords":417,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":42},"100555206","phase-4-beta-blockers-in-takotsubo-syndrome-study-100555206","NCT06509074","Beta-Blockers in Takotsubo Syndrome Study","Beta-Blockers in Takotsubo Syndrome Study: A Randomized Clinical Trial (β-Tako)","β-Tako","Inclusion Criteria:\n\n* Written informed consent.\n* Diagnosis of TTS with exclusion of significant coronary artery disease (CAD) by invasive coronary angiography\n\nExclusion Criteria:\n\n* Patients diagnosed of TTS \\> 48 hours before.\n* Persistent ccardiogenic shock or severe hemodynamic instability\n* Persistent severe (\\>30 mmHg) intraventricular gradient\n* Previous diagnosis of severe valvular or ventricular disease or prior myocardial infarction secondary to atherosclerotic CAD\n* Patients already receiving treatment with betablockers (\\*)\n* Absolute contraindication\u002Findication for beta-blockers (\\*\\*)\n* Poor echocardiographic window\n* Pregnant or breastfeeding women.\n* Participation in another clinical trial.\n\n(\\*) Betablockers at a therapeutic dose at the time of symptom´s onset. (\\*\\*) Close ECG monitoring required in patients with hypotension, bradycardia or cQT interval prolongation",{"count":410,"type":22},200,[352],"The Beta-blockers in Takotsubo syndrome (TTS) (β-Tako) trial, is an academic, pragmatic, prospective, multicenter randomized clinical trial, aiming to assess the efficacy of beta-blockers (BB) in TTS patients. Two-hundred patients with TTS will be randomized (1:1) to BB (n=100) or no BB (n=100). BB with alpha or nitric oxide release activity will be used in the treatment arm. The primary endpoint will be the comparison of the wall motion score index by echocardiography at 7 days. A composite clinical endpoint (death, stroke, admission for recurrent TTS, ACS, heart failure or atrial fibrillation) at 1 year, will be assessed by an independent clinical events committee. Several sub-studies will be performed. The β-Tako trial will inform treatment decisions in this uniquely challenging clinical entity.",[414,415,27,416],"Takotsubo Cardiomyopathy","Beta-blockers","Left Ventricular Function",[414,418,315,419,420,421,422,423,424,425],"beta-blockers","left ventricular function","acute myocardial infarction","acute coronary syndrome","coronary angiography","Normal coronary arteries","Heart failure","stress","2024-08-21",{"date":428,"type":34},"2024-08-26",{"date":430,"type":22},"2024-08",{"date":432,"type":22},"2026-12",{"name":434,"class":41},"Spanish Society of Cardiology",{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":16,"sex":17,"minAge":164,"maxAge":232,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":445,"conditions":446,"keywords":447,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":42},"100474776","normal-reference-range-for-neonatal-echocardiography-100474776","NCT05462301","Normal Reference Range for Neonatal Echocardiography","Normal Reference Range for Neonatal Echocardiography: a Multi-center, Prospective Study","NORRNE","Inclusion Criteria:\n\n* Outpatient or inpatient neonate\n* Gestational age \\> 30weeks and birthweight \\> 1250 grams\n* Appropriate for gestational age\n* Without perinatal asphyxia\n* Without skin lesion on the left chest wall\n* with family informed consent for neonatal echocardiography\n\nExclusion Criteria:\n\n* specialist cardiac ultrasound suggests congenital heart disease;\n* PDA with hemodynamic abnormalities, defined as: PDA \\> 1.5 mm (left-to-right shunt) and left atrial diameter\u002Faortic root \\> 1.5 or the need for the use of inotropes;\n* invasive mechanical ventilation therapy,\n* non-invasive mechanical ventilation with FiO2 \\>0.3\n* major anomalies\n* blood culture-proven neonatal sepsis\n* persistent pulmonary hypertension\n* renal failure\n* necrotizing enterocolitis ≥ stage II\n* post surgery\n* Maternal history of severe anemia, or prenatal massive bleeding",{"count":444,"type":22},1500,"Echocardiography is the main method of bedside examination of neonatal cardiac morphology, which can timely diagnose congenital heart disease and quantitatively assess its severity, but the diagnosis and evaluation process depends on the normal range of neonatal echocardiography.At present, there have been normal reference standards for echocardiography in children and adults at home and abroad, but there is no uniform standard for echocardiographic parameters in newborns, especially premature infants.This study intends to carry out a national multicenter, prospective, observational study to establish the reference range of echocardiography at different time periods after birth in newborns, and stratified according to gestational age, birth weight and gender, to conduct a more accurate hemodynamic assessment of clinically critically ill newborns and guide the treatment of critically ill newborns in real time.",[27],[448,449,450],"Neonatal Echocardiogram","Reference Ranges","Preterm Infants","2024-07-13",{"date":453,"type":34},"2024-07-16",{"date":455,"type":34},"2022-11-15",{"date":457,"type":22},"2024-12-30",{"name":459,"class":41},"Children's Hospital of Chongqing Medical University",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":470,"conditions":471,"keywords":472,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":482,"locationsCount":42},"100499072","algorithms-to-improve-the-accuracy-of-the-echocardiographic-report-100499072","NCT05778500","Algorithms to Improve the Accuracy of the Echocardiographic Report","IMPlementazione di algoRitmi di Assistenza Alla diagnOsi in un Software di Refertazione Computerizzato Che Valuta Anche l'Accuratezza Dell'Esame ECOcardiografico","IMPROVE ECO","Inclusion Criteria:\n\n* Having undergone a clinically-indicated echocardiographic study\n\nExclusion Criteria:\n\n* Denial of the consensus to use individual clinical data for research purposes",{"count":469,"type":22},3500,"This observational study aims to improve the accuracy of the report of the echocardiographic study, making it more consistent with the current international guidelines and reducing the diagnostic mistakes in patients undergoing clinically -indicated echocardiography. The main questions it aims to answer are:\n\n* can the addition of automated diagnostic algorithms help to improve the overall accuracy of the echocardiographic report?",[27],[473,474,475],"Transthoracic echocardiography","Transesophageal echocardiography","Report","2024-04-15",{"date":478,"type":34},"2024-04-16",{"date":480,"type":34},"2020-09-30",{"date":367,"type":22},{"name":483,"class":41},"Istituto Auxologico Italiano",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":17,"minAge":492,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":77,"phases":494,"briefSummary":495,"conditions":496,"keywords":501,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":4},"100505523","preoperative-focused-cardiac-ultrasound-in-hip-fracture-surgery-precho-100505523","NCT05862493","Preoperative Focused Cardiac Ultrasound in Hip Fracture Surgery (PrEcho)","Preoperative Focused Cardiac Ultrasound in Hip Fracture Surgery - Study Protocol for a Randomized Controlled Trial","PrEcho","Inclusion Criteria:\n\n* Patients ≥ 65 years of age, with American Socieity of Anesthesiologists (ASA) physical status classification 2-4, that are scheduled for acute hip fracture surgery (ICD-codes s72.0, s72.00, s72.01, s72.1, s72.2)\n\nExclusion Criteria:\n\n* Metastatic cancer and\u002For suspect pathological fracture.\n* Concurrent other fracture\u002Fsurgery.\n* Reoperation within 72 hours from primary operation.\n* Severe dementia.\n* Preoperative echocardiography for other reason than participation in the study.","65 Years",{"count":140,"type":22},[79],"The primary objective of this study is to investigate the impact of preoperative focused transthoracic ultrasound (FOCUS) on intraoperative hypotension and postoperative complications in hip fracture surgery. Our hypothesis is that a preoperative FOCUS along with a hemodynamic optimization protocol will reduce the occurrence of intraoperative drops in blood pressure and post-operative complications.",[27,497,498,499,500],"Hip Fractures","Risk Assessment","Anesthesia","Hemodynamic Instability",[502,503],"FOCUS","Point-of-care echocardiography","2023-12-07",{"date":506,"type":34},"2023-12-08",{"date":508,"type":22},"2024-02",{"date":432,"type":22},{"name":511,"class":41},"Umeå University"]